Compare Medpace Holdings Inc (MEDP) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 136.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 2,982,924). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| MEDP | VTI | |
|---|---|---|
Market Cap | $16.82B | $2.30T |
Volume | 223,093 | 2,982,924 |
Sector | Health | — |
52-Week High | $630.19 | $384.30 |
52-Week Low | $393.42 | $311.68 |
Typical Hold Time | 14 Days | 131 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
VTI trades at $379.56, down 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad U.S. equity exposure, though key valuation and profitability ratios are not publicly disclosed for the fund itself. Recent news highlights its role in diversified portfolios and long-term growth potential.
The outlook for VTI remains positive given its low-cost, diversified structure and historical performance. Risks include market concentration in top holdings and broader economic volatility. Analyst sentiment is generally favorable for long-term investors seeking total market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
